Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.

NCT04712721 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

14

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons

Conditions

Glioblastoma Multiforme
Brain Neoplasms
Gastroesophageal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: 68Ga-FF58

Sponsor

Novartis Pharmaceuticals